Nirogacestat: First Approval.
Keam SJ.
Drugs · review; journal article · DOI 10.1007/s40265-024-02002-x PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för nirogacestat. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
29 träffarGamma-Secretase Inhibitors Downregulate the Profibrotic NOTCH Signaling Pathway in Recessive Dystrophic Epidermolysis Bullosa.
Condorelli AG, Nobili R, Muglia A, Scarpelli G, Marzuolo E, De Stefanis C, Rota R, Diociaiuti A, Alaggio R, Castiglia D, Odorisio T, El Hachem M, Zambruno G.
J Invest Dermatol · journal article · DOI 10.1016/j.jid.2023.10.045The Notch signaling pathway in desmoid tumor: Recent advances and the therapeutic prospects.
Zheng C, Huang J, Xu G, Li W, Weng X, Zhang S.
Biochim Biophys Acta Mol Basis Dis · review; journal article · DOI 10.1016/j.bbadis.2023.166907Nirogacestat and its potential impact on desmoid tumor.
Rohail S, Fareed A, Taimuri MA, Adnan A.
Rare Tumors · letter; journal article · DOI 10.1177/20363613231182485Nirogacestat effective in desmoid tumours.
Sidaway P.
Nat Rev Clin Oncol · comment; journal article · DOI 10.1038/s41571-023-00758-xNirogacestat and Hypophosphatemia.
Gudsoorkar P, Wanchoo R, Jhaveri KD.
Kidney Int Rep · letter; journal article · DOI 10.1016/j.ekir.2023.04.023Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
Gounder M, Ratan R, Alcindor T, Schöffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B.
N Engl J Med · clinical trial, phase iii; research support, u.s. gov't, p.h.s.; research-article; randomized controlled trial; journal article · DOI 10.1056/nejmoa2210140Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition.
Federman N.
NPJ Precis Oncol · review-article; review; journal article · DOI 10.1038/s41698-022-00308-1Evolving strategies for management of desmoid tumor.
Riedel RF, Agulnik M.
Cancer · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1002/cncr.34332Response of NOTCH1-Activated Tracheal Adenoid Cystic Carcinoma to the Gamma Secretase Inhibitor Nirogacestat.
Kieran R, de Paula BHR, Hubank M, Barker A, Paterson AL, Gilligan D, Doherty GJ.
JCO Precis Oncol · journal article; case reports · DOI 10.1200/po.21.00228Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells.
Du Z, Li L, Sun W, Zhu P, Cheng S, Yang X, Luo C, Yu X, Wu X.
Front Oncol · research-article; journal article · DOI 10.3389/fonc.2021.607291Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Nooka AK, Weisel K, van de Donk NW, Routledge D, Otero PR, Song K, Quach H, Callander N, Minnema MC, Trudel S, Jackson NA, Ahlers CM, Im E, Cheng S, Smith L, Hareth N, Ferron-Brady G, Brouch M, Montes de Oca R, Paul S, Holkova B, Gupta I, Kremer BE, Richardson P.
Future Oncol · clinical trial protocol; journal article · DOI 10.2217/fon-2020-1269Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases.
Takahashi T, Prensner JR, Robson CD, Janeway KA, Weigel BJ.
Pediatr Blood Cancer · journal article; case reports · DOI 10.1002/pbc.28636Nirogacestat suppresses RANKL-Induced osteoclast formation in vitro and attenuates LPS-Induced bone resorption in vivo.
Chen X, Chen X, Zhou Z, Mao Y, Wang Y, Ma Z, Xu W, Qin A, Zhang S.
Exp Cell Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.yexcr.2019.06.015Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma.
Yang X, Xia W, Chen L, Wu CX, Zhang CC, Olson P, Wang XQ.
Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.26209HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.
Du Z, Li L, Sun W, Wang X, Zhang Y, Chen Z, Yuan M, Quan Z, Liu N, Hao Y, Li T, Wang J, Luo C, Wu X.
Int J Oncol · research-article; journal article · DOI 10.3892/ijo.2018.4370Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.
Zheng Y, Wang Z, Ding X, Dong Y, Zhang W, Zhang W, Zhong Y, Gu W, Wu Y, Song X.
Cell Prolif · research-article; journal article · DOI 10.1111/cpr.12424Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.
Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W.
Ann Surg Oncol · multicenter study; clinical trial, phase i; journal article · DOI 10.1245/s10434-017-6082-1Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1-Stat3.
Wu CX, Xu A, Zhang CC, Olson P, Chen L, Lee TK, Cheung TT, Lo CM, Wang XQ.
Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-17-0001Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).
Kummar S, O'Sullivan Coyne G, Do KT, Turkbey B, Meltzer PS, Polley E, Choyke PL, Meehan R, Vilimas R, Horneffer Y, Juwara L, Lih A, Choudhary A, Mitchell SA, Helman LJ, Doroshow JH, Chen AP.
J Clin Oncol · clinical trial, phase ii; research-article; journal article · DOI 10.1200/jco.2016.71.1994Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.
Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, Curigliano G.
Oncotarget · research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.18632/oncotarget.13727A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Papayannidis C, DeAngelo DJ, Stock W, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, Ozeck M, Aster JC, Kuo F, Huang D, Lira PD, McLachlan KR, Kern KA, Garcia-Manero G, Martinelli G.
Blood Cancer J · letter; research support, non-u.s. gov't; clinical trial, phase i · DOI 10.1038/bcj.2015.80Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
Cui D, Dai J, Keller JM, Mizokami A, Xia S, Keller ET.
Clin Cancer Res · research-article; journal article · DOI 10.1158/1078-0432.ccr-15-0242A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.
Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM.
Clin Cancer Res · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-14-0607Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.
Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Lyalin D.
Pediatr Blood Cancer · research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/pbc.25026Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.
Zhang CC, Yan Z, Giddabasappa A, Lappin PB, Painter CL, Zhang Q, Li G, Goodman J, Simmons B, Pascual B, Lee J, Levkoff T, Nichols T, Xie Z.
Cancer Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/cam4.215Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
Zhang CC, Yan Z, Zong Q, Fang DD, Painter C, Zhang Q, Chen E, Lira ME, John-Baptiste A, Christensen JG.
Stem Cells Transl Med · research-article; journal article · DOI 10.5966/sctm.2012-0096Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
Zhang CC, Pavlicek A, Zhang Q, Lira ME, Painter CL, Yan Z, Zheng X, Lee NV, Ozeck M, Qiu M, Zong Q, Lappin PB, Wong A, Rejto PA, Smeal T, Christensen JG.
Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-12-1379Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.
Lanz TA, Wood KM, Richter KE, Nolan CE, Becker SL, Pozdnyakov N, Martin BA, Du P, Oborski CE, Wood DE, Brown TM, Finley JE, Sokolowski SA, Hicks CD, Coffman KJ, Geoghegan KF, Brodney MA, Liston D, Tate B.
J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.110.167379